INOVIO to Host Webinar “DNA Medicines: From COVID-19 to Cancer”

Advertisements
Advertisements

Related Posts:


INOVIO, a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases, cancer, and diseases associated with HPV, today announced it will hold a webinar event on June 1 from 10 AM to noon EDT to detail its proprietary DNA medicines technology and provide updates on INO-4800, its DNA vaccine in Phase 1 clinical development for COVID-19, and INO-5401, its DNA immunotherapy designed to treat glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer. Preclinical data on INO4800 demonstrating robust neutralizing antibody and T cell immune responses was published in the peer-reviewed journal Nature Communications on May 20, 2020. Data demonstrating 85% of newly diagnosed glioblastoma patents were alive 12 months following treatment with INO-5401, in combination with INO-9012 and PD-1 inhibitor Libtayo® (cemiplimab), will be featured at an oral poster presentation at the ASCO 2020 Virtual Scientic Program, May 29-31, 2020.

More Information Here: http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-to-Host-Webinar-DNA-Medicines-From-COVID-19-to-Cancer/default.aspx

Advertisements
Advertisements